H. Olsson

H. Olsson, T. Möller, S. Gudmundsson, 1989, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

In Review

J. Ranstam, H. Olsson, L. Lidgren, 1995, Significance.

Metal-on-metal joint bearings and hematopoetic malignancy

J. Ranstam, H. Olsson, L. Lidgren, 2012, Acta orthopaedica.

NON-HODGKIN'S LYMPHOMA OF THE SKIN AND OCCUPATIONAL EXPOSURE TO HERBICIDES

H. Olsson, L. Brandt, 1981, The Lancet.

Early oral contraceptive use and premenopausal breast cancer--a review of studies performed in southern Sweden.

M. Fernö, J. Ranstam, Å. Borg, 1991, Cancer Detection and Prevention.

Different fractions of human serum glycoproteins bind galectin-1 or galectin-8, and their ratio may provide a refined biomarker for pathophysiological conditions in cancer and inflammatory disease.

M. Fernö, H. Olsson, J. Malmström, 2012, Biochimica et biophysica acta.

BREAST CANCER AND ORAL CONTRACEPTIVES

M. Pike, J. Ranstam, H. Olsson, 1985, The Lancet.

ORAL CONTRACEPTIVE USE AND BREAST CANCER IN YOUNG WOMEN IN SWEDEN

J. Ranstam, H. Olsson, T. Möller, 1985, The Lancet.

Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors

H. Olsson, C. Ingvar, P. Jönsson, 2005, Breast Cancer Research and Treatment.

ORAL CONTRACEPTIVES AND BREAST CANCER

J. Ranstam, H. Olsson, 1987, The Lancet.

A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer

M. Fernö, J. Ranstam, Å. Borg, 1986, Medical oncology and tumor pharmacotherapy.

Guidelines for Follow-Up of Women at High Risk for Inherited Breast Cancer: Consensus Statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer

J. Chang-Claude, K. Heimdal, P. Møller, 2002, Disease markers.

VALIDITY STUDIES OF SOME VARIABLES USED IN CANCER EPIDEMIOLOGY

H. Olsson, C. Ingvar, P. Jönsson, 1984 .

Transcription of human endogenous retroviral sequences related to mouse mammary tumor virus in human breast and placenta: similar pattern in most malignant and nonmalignant breast tissues.

Å. Borg, H. Olsson, J. Blomberg, 1997, AIDS research and human retroviruses.

Recurrence-free survival in breast cancer improved by adjuvant tamoxifen -especially for progesterone receptor positive tumors with a high proliferation

M. Fernö, Å. Borg, H. Olsson, 2004, Breast Cancer Research and Treatment.

With increasing age at tumor diagnosis in familial cancer: Cancer is limited to fewer organs

H. Olsson, 2015 .

Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.

M. King, Å. Borg, O. Johannsson, 1996, American journal of human genetics.

Clinical and histopathological characteristics in relation to aetiological risk factors in cutaneous melanoma: a population-based study.

H. Olsson, C. Ingvar, A. Måsbäck, 1999, Melanoma research.

Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.

S. Puig, D. Bishop, D. Elder, 2016, The Journal of investigative dermatology.

The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression.

Å. Borg, H. Olsson, Hampus Olsson, 1992, Cancer research.

Image cytometric DNA analysis in human breast cancer analysis may add prognostic information in diploid cases with low S-phase fraction by flow cytometry.

M. Fernö, H. Olsson, H. Sigurdsson, 1992, Cytometry.

Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study.

H. Olsson, O. Bratt, U. Kristoffersson, 1999, European journal of cancer.

A novel p53 germline alteration identified in a late onset breast cancer kindred.

Å. Borg, O. Johannsson, H. Olsson, 1996, Oncogene.

Chromosome aberrations in prophylactic mastectomies from women belonging to breast cancer families

Å. Borg, H. Olsson, F. Mitelman, 1996 .

Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma.

Thomas M. Keane, K. Brown, J. Trent, 2015, Journal of the National Cancer Institute.

Melanoma and nonmelanoma skin cancer in patients with multiple tumours—evidence for new syndromes in a population‐based study

K. Nielsen, Å. Borg, H. Olsson, 2004, The British journal of dermatology.

Epidemiology and Health Services Research Melanoma and nonmelanoma skin cancer in patients with multiple tumours—evidence for new syndromes in a population-based study

K. Nielsen, H. Olsson, C. Ingvar, 2004 .

Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.

B. Ponder, H. Olsson, P. Radice, 1998, The New England journal of medicine.

hMLH1, hMSH2 and hMSH6 mutations in hereditary non‐polyposis colorectal cancer families from Southern Sweden

Å. Borg, H. Olsson, P. Mangell, 1999, International journal of cancer.

Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype

K. Nielsen, Å. Borg, H. Olsson, 2010, Melanoma research.

Phenocopies in melanoma-prone families with germ-line CDKN2A mutations

H. Olsson, M. Tucker, A. Goldstein, 2017, Genetics in Medicine.

The risk of malignant tumours in first-degree relatives of men with early onset prostate cancer: a population-based cohort study.

H. Olsson, O. Bratt, U. Kristoffersson, 1997, European journal of cancer.

A review of the epidemiology of soft tissue sarcoma.

H. Olsson, 1999, Acta orthopaedica Scandinavica. Supplementum.

Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones.

M. Fernö, J. Ranstam, Å. Borg, 1991, Journal of the National Cancer Institute.

Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls

Tim K. Lee, J. Barrett, D. Bishop, 2009, International journal of epidemiology.

Gender and time differences in initial location and histological grade of non-Hodgkin's lymphomas in Southern Sweden.

H. Olsson, T. Möller, H. Anderson, 2001, Acta oncologica.

Tumors associated with Hereditary Nonpolyposis Colorectal Cancer: Defective Mismatch Repair and Familial Risk of Cancer Ericson Lindquist, Kajsa

H. Olsson, A. Bladström, 2005 .

The prognosis of breast cancer in males. A report of 335 cases.

H. Olsson, S. Dische, M. Durand, 1993, Cancer.

Problems in assessing multiple cutaneous melanoma. A review on the accuracy of a population based cancer registry.

H. Olsson, A. Måsbäck, G. Andersson, 2010, Cancer epidemiology.

Deletion of 14q in non‐Hodgkin's lymphoma

H. Olsson, F. Mitelman, N. Mandahl, 1990, European journal of haematology.

Relationship between cytogenetic findings and histopathology in non-Hodgkin lymphoma.

H. Olsson, F. Mitelman, S. Heim, 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology.

Cytogenetic studies in non-Hodgkin lymphomas--results from surgical biopsies.

H. Olsson, F. Mitelman, S. Heim, 2008, Hereditas.

Fine needle aspiration biopsy: a useful tool in tumor cytogenetics with special reference to malignant lymphomas.

H. Olsson, F. Mitelman, U. Kristoffersson, 1981, Cancer genetics and cytogenetics.

Southern travelling habits with special reference to tumour site in Swedish melanoma patients.

H. Olsson, C. Ingvar, P. Jönsson, 1992, Anticancer Research.

Lower breast cancer survival in mothers of children with a malignancy: a national study

H. Olsson, A. Bladström, S. Magnusson, 2008, British Journal of Cancer.

The variability of urographic findings in posterior urethral valves

H. Olsson, O. Eklöf, 2004, Pediatric Radiology.

No abnormal C-band polymorphism in lung cancer patients.

H. Olsson, F. Mitelman, R. Berger, 2008, Hereditas.

C-band polymorphism in non-Hodgkin lymphoma.

H. Olsson, F. Mitelman, R. Berger, 2008, Hereditas.

C-band heteromorphism in breast cancer patients.

H. Olsson, F. Mitelman, R. Berger, 1985, Cancer genetics and cytogenetics.

Occupational exposure to organic solvents and Hodgkin's disease in men. A case-referent study.

H. Olsson, L. Brandt, 1980, Scandinavian journal of work, environment & health.

Alcohol, cigarette smoking, and the risk of breast cancer.

J. Ranstam, H. Olsson, 1995, Cancer detection and prevention.

Normal frequency of structural chromosome aberrations in fibroblasts from patients with non-Hodgkin's lymphoma.

H. Olsson, F. Mitelman, F. Mertens, 2008, Hereditas.

Chromosome I alterations in breast cancer: Allelic loss on Ip and Iq Is related to lymphogenic metastases and poor prognosis

Å. Borg, H. Olsson, Qiu‐xia Zhang, 1992 .

One or multiple samplings for flow cytometric DNA analyses in breast cancer-prognostic implications?

M. Fernö, H. Olsson, H. Sigurdsson, 1992, Cytometry.

In Vivo Evidence in Humans of an Association Between ADP-Ribosylation Levels in Mononuclear Leukocytes and Immune Function

H. Olsson, L. Salford, R. Pero, 1992 .

Elevation of ADP-ribosylation as an indicator of mononuclear leucocyte responsiveness in breast cancer patients treated with tamoxifen.

H. Olsson, R. Pero, F. Killander, 1992, European journal of cancer.

Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis.

Å. Borg, H. Olsson, E. Wenngren, 1992, Genes, chromosomes & cancer.

Cytogenetic studies in non-Hodgkin lymphomas--results from fine-needle aspiration samples.

H. Olsson, F. Mitelman, M. Åkerman, 2008, Hereditas.

Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study.

S. Puig, N. Hayward, H. Olsson, 2014, The Journal of investigative dermatology.

Survival in breast cancer and age at start of oral contraceptive usage.

J. Ranstam, H. Olsson, L. Janzon, 1991, Anticancer research.

Oral-Contraceptive Use and the Risk of Breast Cancer

S. Shapiro, J. Ranstam, P. Wingo, 1987 .

Risk of non-Hodgkin's lymphoma among men occupationally exposed to organic solvents.

H. Olsson, L. Brandt, Håkan Olsson, 1988, Scandinavian journal of work, environment & health.

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions

H A Risch, J. Hopper, M. Southey, 2008, British Journal of Cancer.

MYB oncogene amplification in hereditary BRCA1 breast cancer.

J M Trent, J Isola, J. Trent, 2000, Cancer research.

Advances in Brief MYB Oncogene Amplification in Hereditary BRCA 1 Breast Cancer 1

J. Trent, D. Duggan, Å. Borg, 2000 .

Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer

L. Kiemeney, R. Vierkant, Jingmei Li, 2020, bioRxiv.

Microcalorimetric investigation of cell metabolism in tumour cells from patients with non-Hodgkin lymphoma (NHL).

H. Olsson, L. Brandt, M. Monti, 2009, Scandinavian journal of haematology.

Heat production rate in blood lymphocytes as a prognostic factor in non‐Hodgkin's lymphoma

H. Olsson, L. Brandt, M. Monti, 1990, European journal of haematology.

Mitotic activity in non-Hodgkin's lymphoma. Relation to the Kiel classification and to prognosis.

H. Olsson, L. Brandt, M. Åkerman, 1987, British Journal of Cancer.

Metabolic activity of lymphoma cells and clinical course in non-Hodgkin lymphoma (NHL).

H. Olsson, I. Wadsö, H. Olsson, 2009, Scandinavian journal of haematology.

Uptake of thymidine in lymphoma cells obtained through fine-needle aspiration biopsy. Relation to prognosis in non-Hodgkin's lymphomas.

H. Olsson, L. Brandt, M. Monti, 1981, European journal of cancer & clinical oncology.

Time to Diagnosis of Melanoma: Same Trend in Different Continents

S. Menzies, H. Olsson, A. Blum, 2007, Journal of cutaneous medicine and surgery.

Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma

Marko Hočevar, Kevin M. Brown, Florence Demenais, 2015, Nature Genetics.

Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility

Blair H. Smith, Jeffrey E. Lee, G. Abecasis, 2020, Nature Genetics.

Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data

H. Olsson, Shamik Mitra, C. Ingvar, 2019, Scientific Reports.

Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes

H. Olsson, H. Kwon, C. Ingvar, 2020, Cancers.

Tumour biological features of BRCA1-induced breast and ovarian cancer.

Å. Borg, O. Johannsson, H. Olsson, 1997, European journal of cancer.

Estrogen and Progesterone Receptor Analyses in More Than 4000 Human Breast Cancer Samples: A Study with Special Reference to Age at diagnosis and stability of analyses

M. Fernö, Å. Borg, H. Olsson, 1990 .

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

J. S. Hoffman, W. Chung, V. Pankratz, 2012, Human mutation.

Indicators of prognosis in node-negative breast cancer.

M. Fernö, Å. Borg, H. Olsson, 1990, The New England journal of medicine.

Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer

A. Whittemore, R. Nussbaum, B. Fridley, 2014, Clinical Cancer Research.

UvA-DARE ( Digital Academic Repository ) In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid ( LNA ) antisense oligonucleotides

Frank Baas, F. Baas, H. Olsson, 2017 .

A variant in FTO shows association with melanoma risk not due to BMI

Marko Hočevar, Florence Demenais, Kari Stefansson, 2013, Nature Genetics.

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

D. Schadendorf, H. Olsson, J. Wargo, 2020, Nature.

Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32.

Å. Borg, H. Olsson, C. Ingvar, 2005, Journal of the National Cancer Institute.

Cancer risks in BRCA2 mutation carriers.

H. Olsson, 1999, Journal of the National Cancer Institute.

High frequency of allelic imbalance at the BRCA1 region on chromosome 17q in both familial and sporadic ductal breast carcinomas.

Å. Borg, O. Johannsson, H. Olsson, 1994, Journal of the National Cancer Institute.

Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.

Å. Borg, N. Loman, O. Johannsson, 1997, American journal of human genetics.

High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.

Kerstin, Å. Borg, O. Johannsson, 2000, Journal of the National Cancer Institute.

NF1‐mutated melanoma tumors harbor distinct clinical and biological characteristics

L. Saal, N. Hayward, H. Olsson, 2017, Molecular oncology.

The human melanoma proteome atlas—Defining the molecular pathology

H. Kato, H. Olsson, P. Horváth, 2021, Clinical and translational medicine.

Cell of Origin of Breast Cancer: An Updated Hypothesis Merging Epidemiological Data with Molecular Biology

H. Olsson, 2013 .

Cancer morbidity in blood recipients--results of a cohort study.

H. Olsson, J. Blomberg, T. Möller, 1993, European journal of cancer.

Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer

Gord Glendon, Lesley McGuffog, Daniel Barrowdale, 2012 .

Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study

J. Chang-Claude, R. Eeles, D. Easton, 2009, Cancer Epidemiology Biomarkers & Prevention.

Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.

P. Møller, Å. Borg, N. Loman, 2001, Human molecular genetics.

Epithelial and Stromal MicroRNA Signatures of Columnar Cell Hyperplasia Linking Let-7c to Precancerous and Cancerous Breast Cancer Cell Proliferation

Crispin J. Miller, A. Howell, H. Olsson, 2014, PloS one.

Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma

K. Nielsen, M. Ringnér, K. Brown, 2020, Molecular oncology.

The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response

H. Olsson, Rita Cabrita, M. Lauss, 2020, Cancers.

Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma

M. Ringnér, Å. Borg, H. Olsson, 2012, Clinical Cancer Research.

Prognostic implication of cytogenetic findings in 106 patients with non-Hodgkin lymphoma.

J. Ranstam, H. Olsson, F. Mitelman, 1987, Cancer genetics and cytogenetics.

Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations

S. Chanock, H. Olsson, M. Yeager, 2016, Human Genetics.

Breakprone chromosome bands in fibroblasts from patients with non-Hodgkin's lymphoma do not coincide with bands involved in primary rearrangements in non-Hodgkin's lymphomas.

H. Olsson, F. Mitelman, F. Mertens, 2008, Hereditas.

One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.

Å. Borg, N. Loman, H. Olsson, 2004, European journal of cancer.

Clinical and histopathological features of malignant melanoma in germline CDKN2A mutation families

Å. Borg, H. Olsson, C. Ingvar, 2002, Melanoma research.

The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma.

D. Schadendorf, H. Olsson, Rita Cabrita, 2019, Cell reports.

Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy

Johan Staaf, Frida Rosengren, Markus Ringnér, 2015, Oncotarget.

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

S. Puig, L. Thomas, S. Richard, 2011, Nature.

Molecular and Cellular Pathobiology The Retinoblastoma Gene Undergoes Rearrangements in BRCA 1-De fi cient Basal-like Breast Cancer

M. Ringnér, L. Saal, M. Fernö, 2012 .

Molecular and genetic diversity in the metastatic process of melanoma

L. Saal, H. Olsson, M. Lauss, 2014, The Journal of pathology.

Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort

Å. Borg, H. Olsson, P. Broberg, 2015, Genes, chromosomes & cancer.

Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.

Å. Borg, N. Loman, O. Johannsson, 2001, Journal of the National Cancer Institute.

Prognosis and clinical presentation of BRCA2-associated breast cancer.

Å. Borg, N. Loman, O. Johannsson, 2000, European journal of cancer.

BRCA1-positive patients are small for gestational age compared with their unaffected relatives.

Å. Borg, O. Johannsson, H. Olsson, 1998, European journal of cancer.

The Effect on Melanoma Risk of Genes Previously Associated With Telomere Length

Jeffrey E. Lee, S. Puig, E. Gillanders, 2014, Journal of the National Cancer Institute.

Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.

J Isola, Å. Borg, O. Kallioniemi, 1997, Cancer research.

The Menstrual Cycle and Risk of Breast Cancer: A Review

H. Olsson, M. L. Olsson, 2020, Frontiers in Oncology.

Characterization of a Novel Breast Carcinoma Xenograft and Cell Line Derived from a BRCA1 Germ-Line Mutation Carrier

I. Hedenfalk, O. Johannsson, H. Olsson, 2003, Laboratory Investigation.

Mitotic activity and survival in advanced non-Hodgkin's lymphoma of unfavourable histology.

H. Olsson, L. Brandt, M. Åkerman, 1990, European journal of cancer.

Survival following combination chemotherapy in advanced high grade non‐Hodgkin's lymphomas: Relation to proliferative activity of the lymphoma cells

H. Olsson, L. Brandt, 1987, European journal of haematology.

The prognosis of breast cancer in males a report of 335 cases

H. Olsson, S. Dische, M. Durand, 1993 .

Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.

M. Fernö, H. Olsson, R. Parwaresch, 2001, Human pathology.

Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis.

M. Fernö, Å. Borg, H. Olsson, 1991, British Journal of Cancer.

Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome.

M. Fernö, Å. Borg, H. Olsson, 1992, Acta oncologica.

ERBB2 amplification in breast cancer with a high rate of proliferation.

M. Fernö, Å. Borg, H. Olsson, 1991, Oncogene.

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

S. Kauppinen, H. Olsson, C. Ingvar, 2020, bioRxiv.

Title: PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

S. Kauppinen, H. Olsson, C. Ingvar, 2020 .

Prognostic implications of cytogenetic findings in kidney cancer.

M. Fernö, H. Olsson, F. Mitelman, 1997, British journal of urology.

Feasibility study on measuring selected proteins in malignant melanoma tissue by SRM quantification.

H. Olsson, C. Ingvar, G. Jönsson, 2014, Journal of proteome research.

Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers

Å. Borg, N. Loman, H. Olsson, 1998, The Lancet.

Head trauma and exposure to prolactin-elevating drugs as risk factors for male breast cancer.

J. Ranstam, H. Olsson, Jonas Ranstam, 1988, Journal of the National Cancer Institute.

The clinicopathological and gene expression patterns associated with ulceration of primary melanoma

H. Olsson, M. Lauss, K. Jirström, 2015, Pigment cell & melanoma research.

Analysis of Alpha-Synuclein in Malignant Melanoma – Development of a SRM Quantification Assay

H. Olsson, C. Ingvar, G. Jönsson, 2014, PloS one.

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions

J. Hopper, D. Easton, P. Pharoah, 2008, British Journal of Cancer.

A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

W. Chung, V. Pankratz, F. Couch, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.

F. Couch, B. Karlan, J. Benítez, 2011, Journal of the National Cancer Institute.

Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay.

M. Fernö, Å. Borg, H. Olsson, 1996, European journal of cancer.

Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group.

M. Fernö, Å. Borg, H. Olsson, 1994, European journal of cancer.

Neuroendocrine differentiation in male breast carcinomas

H. Olsson, J. Alumets, P. Alm, 1992, Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS).

Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer.

M. Fernö, H. Olsson, R. Parwaresch, 1999, Journal of the National Cancer Institute.

Perceptions of genetic research and testing among members of families with an increased risk of malignant melanoma.

H. Olsson, C. Ingvar, O. Baron-Epel, 2012, European journal of cancer.

Risk of ovarian cancer in breast-cancer patients with a family history of either

H. Olsson, S. Narod, 2003, The Lancet.

Occupational Exposures and Non-Hodgkin's Lymphoma in Southern Sweden

H. Olsson, T. Kauppinen, L. Brandt, 2004, International journal of occupational and environmental health.

ociation of the Variants CASP 8 D 302 H and CASP 10 0 I with Breast and Ovarian Cancer Risk in B & P A 1 and BRCA 2 Mutation Carriers

Rob, T. Rebbeck, J. Benítez, 2010 .

An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study

D. Schadendorf, S. Puig, J. Barrett, 2013, Pigment cell & melanoma research.

Chromosome aberrations in prophylactic mastectomies from women belonging to breast cancer families.

Å. Borg, H. Olsson, F. Mitelman, 1996, Genes, chromosomes & cancer.

Investigation of a putative melanoma susceptibility locus at chromosome 3q29.

H. Olsson, C. Ingvar, G. Jönsson, 2014, Cancer genetics.

Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study

S. Puig, E. Gillanders, D. Elder, 2010, Journal of the National Cancer Institute.

Galectin-1-Binding Glycoforms of Haptoglobin with Altered Intracellular Trafficking, and Increase in Metastatic Breast Cancer Patients

M. Fernö, H. Olsson, Cecilia Cederfur, 2011, PloS one.

High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer

M. Ringnér, Å. Borg, I. Hedenfalk, 2011, Breast Cancer Research and Treatment.

CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk

Å. Borg, H. Olsson, O. Bratt, 1999, British Journal of Cancer.

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.

M. Fernö, Å. Borg, H. Olsson, 1994, Cancer letters.

ASBESTOS EXPOSURE AND NON-HODGKIN'S LYMPHOMA

H. Olsson, L. Brandt, 1983, The Lancet.

Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review

H. Olsson, C. Ingvar, A. Måsbäck, 2001, Melanoma research.

A new look at drugs targeting malignant melanoma—An application for mass spectrometry imaging

H. Olsson, C. Ingvar, G. Jönsson, 2014, Proteomics.

The clinical significance of BRAF and NRAS mutations in a clinic‐based metastatic melanoma cohort

K. Nielsen, H. Olsson, K. Harbst, 2013, The British journal of dermatology.

High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families

Å. Borg, H. Olsson, C. Ingvar, 2014, Journal of Medical Genetics.

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations

S. Puig, H. Olsson, M. Lauss, 2018, Journal of Medical Genetics.

CM-Score: a validated scoring system to predict CDKN2A germline mutations in melanoma families from Northern Europe

H. Olsson, O. Dekkers, C. V. van Asperen, 2018, Journal of Medical Genetics.

Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.

K. Nielsen, H. Olsson, G. Jönsson, 2016, Journal of the National Cancer Institute.

CDKN2a mutation‐negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies

Johan Hansson, Göran Jönsson, H. Olsson, 2015, International journal of cancer.

Tumor genetic heterogeneity analysis of chronic sun‐damaged melanoma

K. Nielsen, H. Olsson, M. Lauss, 2019, Pigment cell & melanoma research.

Confirmed cancer trends in families of patients with multiple cancers including cutaneous melanoma

K. Nielsen, Å. Borg, H. Olsson, 2007, The British journal of dermatology.

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.

K. Brown, G. Mann, N. Hayward, 2019, Melanoma research.

Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables.

Å. Borg, H. Olsson, B. Agnarsson, 2004, Anticancer Research.

Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers.

Å. Borg, N. Loman, O. Johannsson, 1999, European journal of cancer.

Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden.

J. Ranstam, H. Olsson, T. Möller, 1989, Journal of the National Cancer Institute.

Breast cancer and the pill.

J. Ranstam, H. Olsson, 1989, British Journal of Cancer.

Oral contraceptives and breast cancer. A review.

H. Olsson, 1989, Acta oncologica.

Relation between tumour size and plasma prolactin levels in premenopausal patients with breast carcinoma. A preliminary report.

J. Ranstam, H. Olsson, M. Landin-Olsson, 1985, Acta radiologica. Oncology.

Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels.

M. Fernö, J. Ranstam, Å. Borg, 1990, British Journal of Cancer.

Risk Factors of Breast Cancer in Relation to a Family History of Breast Cancer in Southern Sweden1

J. Ranstam, H. Olsson, U. Kristoffersson, 1985 .

A familial syndromic association between cutaneous malignant melanoma and neural system tumours: reply from authors

H. Olsson, C. Ingvar, A. Måsbäck, 2004 .

Reproductive events, occurring in adolescence at the time of development of reproductive organs and at the time of tumour initiation, have a bearing on growth characteristics and reproductive hormone regulation in normal and tumour tissue investigated decades later--a hypothesis.

H. Olsson, Hampus Olsson, 1989, Medical hypotheses.

Diagnosis and prognosis of breast and ovarian cancer A population-based study of 234 women

H. Olsson, A. Håkansson, H. Thulesius, 2004, Acta oncologica.

Expression of cyclins E, A, and B, and prognosis in lymph node‐negative breast cancer

M. Fernö, H. Olsson, R. Parwaresch, 2003, The Journal of pathology.

Relation between the rate of tumour cell proliferation and latency time in radiation associated breast cancer

M. Fernö, H. Olsson, B. Baldetorp, 2003, BMC Cancer.

Correlation between p53, c‐erbB‐2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node‐negative breast carcinomas: prognostic implications

M. Fernö, H. Olsson, R. Parwaresch, 1999, The Journal of pathology.

Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985

H. Olsson, C. Ingvar, A. Måsbäck, 1997, Cancer.

Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status

Å. Borg, N. Loman, H. Olsson, 2003, Breast Cancer Research.

High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer

Å. Borg, N. Loman, H. Olsson, 2014, Breast Cancer Research and Treatment.

High frequency of microsatellite instability and loss of mismatch‐repair protein expression in patients with double primary tumors of the endometrium and colorectum

H. Olsson, G. Möslein, M. Nilbert, 2002, Cancer.

Somatic frameshift alterations in mononucleotide repeat‐containing genes in different tumor types from an HNPCC family with germline MSH2 mutation

H. Olsson, M. Nilbert, M. Planck, 2000, Genes, chromosomes & cancer.

Effect of pregnancy on prognosis for young women with breast cancer

K. Hess, H. Olsson, S. Dische, 1994, The Lancet.

Correlation of histopathologic characteristics to protein expression and function in malignant melanoma

H. Olsson, C. Ingvar, G. Jönsson, 2017, PloS one.

Early oral contraceptive use as a prognostic factor in breast cancer.

M. Fernö, J. Ranstam, Å. Borg, 1988, Anticancer research.

Reproducibility of a self-administered questionnaire for assessment of melanoma risk.

H. Olsson, C. Ingvar, H. Anderson, 1996, International journal of epidemiology.

Estrogen Receptor Content in Malignant Breast Tumors in Men—a Review

H. Olsson, 2000, Journal of Mammary Gland Biology and Neoplasia.

A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes

Andreas Ziegler, Victor Siskind, Marianne Berwick, 2009, International journal of cancer.

Use of sunbeds or sunlamps and malignant melanoma in southern Sweden.

H. Olsson, C. Ingvar, P. Jönsson, 1994, American journal of epidemiology.

Risk of cutaneous malignant melanoma in relation to use of sunbeds: further evidence for UV-A carcinogenicity

H. Olsson, C. Ingvar, A. Måsbäck, 2000, British Journal of Cancer.

Genetic variant of the human homologous recombination-associated gene RMI1 (S455N) impacts the risk of AML/MDS and malignant melanoma.

H. Olsson, M. Höglund, C. Ingvar, 2007, Cancer letters.

Genetic testing for melanoma.

S. Puig, D. Elder, N. Hayward, 2002, The Lancet. Oncology.

Inherited variation in the PARP1 gene and survival from melanoma

Dirk Schadendorf, Susana Puig, Johan Hansson, 2014, International journal of cancer.

Development and Validation of a Melanoma Risk Score Based on Pooled Data from 16 Case–Control Studies

Tim K. Lee, A. Ziegler, J. Barrett, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Increased cancer risks among arthroplasty patients: 30 year follow-up of the Swedish Knee Arthroplasty Register.

J. Ranstam, H. Olsson, L. Lidgren, 2011, European journal of cancer.

Cytogenetic studies in Hodgkin's disease.

H. Olsson, F. Mitelman, N. Mandahl, 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology.

Near-haploidy in a case of plasmocytoma.

H. Olsson, F. Mitelman, D. Kelly, 1986, Cancer genetics and cytogenetics.

Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden

H. Olsson, C. Ingvar, A. Bladström, 2003, Cancer.

Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer.

H. Grönberg, H. Olsson, J. Damber, 2000, European journal of cancer.

Oral contraceptive use among young women in southern Sweden.

J. Ranstam, H. Olsson, 1993, Journal of epidemiology and community health.

Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study

J. Lapins, H. Olsson, C. Ingvar, 2020, Journal of the National Cancer Institute.

Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions

S. Puig, E. Gillanders, K. Brown, 2014, International journal of cancer.

Analysis of protein expression in pure cell nuclei populations isolated from human breast cancer tissue by DNA flow cytometric sorting.

H. Olsson, C. Ingvar, M. Johansson, 2010, Journal of proteomics.

A Protein Deep Sequencing Evaluation of Metastatic Melanoma Tissues

H. Olsson, B. Döme, C. Ingvar, 2015, PloS one.

Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies

D. Easton, J. Hopper, D. Easton, 2005, Journal of Medical Genetics.

Cutaneous malignant melanoma in south Sweden 1965, 1975, and 1985. A histopathologic review.

H. Olsson, C. Ingvar, A. Måsbäck, 1994, Cancer.

An updated review of the epidemiology of soft tissue sarcoma

H. Olsson, 2004, Acta orthopaedica Scandinavica. Supplementum.

Evidence for SMAD 3 as a modifier of breast cancer risk in BRCA 2 mutation carriers

V. Pankratz, F. Couch, T. Rebbeck, 2010 .

Supradiaphragmatic presentation of non-Hodgkin's lymphoma in men occupationally exposed to organic solvents.

H. Olsson, L. Brandt, 2009, Acta medica Scandinavica.

Novel functional proteins coded by the human genome discovered in metastases of melanoma patients

H. Olsson, H. Kwon, C. Ingvar, 2019, Cell Biology and Toxicology.

University of Groningen Novel functional proteins coded by the human genome discovered in metastases of melanoma patients Sanchez,

H. Olsson, H. Kwon, C. Ingvar, 2019 .

At what age do sunburn episodes play a crucial role for the development of malignant melanoma.

H. Olsson, C. Ingvar, J. Westerdahl, 1994, European journal of cancer.

Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age.

M. Fernö, J. Ranstam, Å. Borg, 1987, Anticancer research.

The number of menstrual cycles prior to the first full term pregnancy an important risk factor of breast cancer?

J. Ranstam, H. Olsson, M. Landin Olsson, 1987, Acta oncologica.

Coincidental occurrence of actinomycosis and Ewing's sarcoma in a child

H. Olsson, O. Björk, O. Eklöf, 2004, Pediatric Radiology.

Familial testicular cancer in Norway and southern Sweden.

K. Heimdal, S. Fosså, H. Olsson, 1996, British Journal of Cancer.

Breast cancer and oral contraceptives [letter]

J. Ranstam, H. Olsson, T. Möller, 1985 .

Genetic predisposition to breast cancer.

Å. Borg, H. Olsson, 1996, Acta oncologica.

Sons of men with prostate cancer: their attitudes regarding possible inheritance of prostate cancer, screening, and genetic testing.

H. Olsson, O. Bratt, U Kristoffersson, 1997, Urology.

Late age at first full-term pregnancy as a risk factor for women with malignant lymphoma.

J. Ranstam, H. Olsson, M. L. Olsson, 1990, Neoplasma.

Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency

H. Cunliffe, I. Hedenfalk, H. Olsson, 2010, Genes, chromosomes & cancer.

Survival in women with breast cancer having children with pediatric tumors--A nationwide cancer register study.

H. Olsson, A. Bladström, 2006, Journal of Clinical Oncology.

Relationship of progesterone-receptor positivity in malignant breast tumors to reproductive status of women at tumor initiation--results from patients with possible radiation-induced tumors.

M. Fernö, Å. Borg, H. Olsson, 1990, Journal of the National Cancer Institute.

Reduced cancer morbidity and mortality in a prospective cohort of women with distal forearm fractures.

H. Olsson, G. Hägglund, Håkan Olsson, 1992, American journal of epidemiology.

Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT.

S. Puig, D. Bishop, D. Elder, 2019, Journal of the American Academy of Dermatology.

Familial risk of tumors associated with hereditary non-polyposis colorectal cancer: a Swedish population-based study

H. Olsson, M. Nilbert, H. Anderson, 2004, Scandinavian journal of gastroenterology.

A segregation analysis of testicular cancer based on Norwegian and Swedish families.

K. Heimdal, H. Olsson, S. Tretli, 1997, British Journal of Cancer.

St Gallen molecular subtypes in screening‐detected and symptomatic breast cancer in a prospective cohort with long‐term follow‐up

M. Fernö, H. Olsson, P. Bendahl, 2016, The British journal of surgery.

Estrogen and progesterone receptor analyses in more than 4,000 human breast cancer samples. A study with special reference to age at diagnosis and stability of analyses. Southern Swedish Breast Cancer Study Group.

M. Fernö, Å. Borg, H. Olsson, 1990, Acta oncologica.

Endogenous expression mapping of malignant melanoma by mass spectrometry imaging

H. Olsson, H. Kwon, C. Ingvar, 2018, Clinical and Translational Medicine.

Do clonal chromosome abnormalities prognosticate early relapse in Hodgkin's disease?

H. Olsson, F. Mitelman, N. Mandahl, 1988, Cancer genetics and cytogenetics.

Correlation between karyotypic pattern and clinicopathologic features in 125 breast cancer cases

H. Olsson, F. Mitelman, C. Ingvar, 1996, International journal of cancer.

Risk of cancer in relatives of testicular cancer patients.

K. Heimdal, S. Fosså, H. Olsson, 1996, British Journal of Cancer.

Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

S. Puig, L. Thomas, S. Richard, 2015, Nature.

Relation between age of mothers with breast cancer and sex of their children.

H. Olsson, L. Brandt, 1980, British medical journal.

Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement.

J. Ranstam, H. Olsson, P. Bygren, 1998, Journal of the American Society of Nephrology : JASN.

Correlation between p53, c‐erbB‐2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node‐negative breast carcinomas: prognostic implications

M. Fernö, H. Olsson, R. Parwaresch, 1999, The Journal of pathology.

Proliferative activity and number of clonal chromosome aberrations in non-Hodgkin's lymphomas.

H. Olsson, L. Brandt, U. Kristoffersson, 2009, Scandinavian journal of haematology.

Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma

D. Schadendorf, H. Olsson, J. Wargo, 2020, Nature.

Cutaneous malignant melanoma in South Sweden 1965, 1975, and 1985. A histopathologic review

H. Olsson, C. Ingvar, A. Måsbäck, 1994, Cancer.

Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility

Blair H. Smith, Jeffrey E. Lee, G. Abecasis, 2020, Nature Genetics.

BRCA1 mutations and survival in women with ovarian cancer.

J. Ranstam, Å. Borg, O. Johannsson, 1997, The New England journal of medicine.

Trisomy 5 and t(5;14)(q11;q32) as the sole abnormalities in two different clones from a centroblastic non-Hodgkin's lymphoma.

H. Olsson, F. Mitelman, N. Mandahl, 1988, Cancer genetics and cytogenetics.

Curative therapies in cancer: A perspective

H. Olsson, 2019, Trends in Research.

Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma

D. Schadendorf, S. Puig, E. Gillanders, 2015, Nature Genetics.

Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma.

Å. Borg, H. Olsson, M. Lauss, 2016, Cancer research.

Development and Validation of a Melanoma Risk Score Based on Pooled Data from 16 Case–Control Studies

Tim K. Lee, A. Ziegler, J. Barrett, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Novel functional proteins coded by the human genome discovered in metastases of melanoma patients

H. Olsson, H. Kwon, C. Ingvar, 2019, Cell Biology and Toxicology.

Male gynecomastia and risk for malignant tumours – a cohort study

H. Olsson, P. Alm, A. Bladstrom, 2002, BMC Cancer.

Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.

K. Nielsen, H. Olsson, G. Jönsson, 2016, Journal of the National Cancer Institute.

Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma

D. Schadendorf, H. Olsson, J. Wargo, 2020, Nature.

Diagnosis of deep vein thrombosis with 99Tcm-plasmin.

H. Olsson, L. Adolfsson, I. Nordenfelt, 2009, Acta medica Scandinavica.

CDKN2a mutation‐negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies

H. Olsson, G. Jönsson, J. Hansson, 2015, International journal of cancer.